Celebrating novel cancer drugs
2003
Celebrating Novel Cancer Drugs
Editorial
Author Information
Author(s): Weiss Robin A
Primary Institution: Cancer Research UK
Conclusion
The Phase I/II Clinical Trials Committee has significantly contributed to international anticancer drug discovery and evaluation.
Supporting Evidence
- The Phase I/II Clinical Trials Committee has selected 89 agents for 85 Phase I trials.
- 30 agents have progressed to further clinical investigation.
- The Committee has won respect from both UK and international cancer research communities.
Takeaway
A group in the UK has helped develop new cancer drugs over the last 20 years, making important decisions about which drugs to test and when to stop testing those that don't work.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website